Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co. develops gene therapy product candidates designed to provide efficacy by inducing sustained expression of a therapeutic protein. Co.'s main capabilities include vector discovery, preclinical and clinical development, and in-house manufacturing knowledge, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. Co.'s lead product candidate ADVM-022 is a single intravitreal injection gene therapy targeting the treatment of wet age-related macular degeneration and diabetic retinopathy. The ADVM YTD return is shown above.
The YTD Return on the ADVM YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ADVM YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADVM YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|